London: The COVID-19 pandemic could cause a short-term decline in life expectancy in the severely affected areas of the world. It will certainly happen unless the spread of the disease is contained, according to a study. The research has been published in the journal ‘PLOS ONE’. It examined the impact of COVID-19-related deaths on life expectancy for four broad world regions across multiple rates of infection and age groups.
“Our study provides the first assessment of the potential impact of COVID-19 on period life expectancies. This is based on a range of scenarios of prevalence rates over a one-year period,” said Guillaume Marois. He is from the International Institute for Applied Systems Analysis (IIASA) in Austria, who led the study.
Period life expectancy is a measure of the number of years that an average person may expect to live. Prevalence is the proportion of a particular population found to be affected by a disease at a specific time.
The researchers noted that improved healthcare, socio-economic conditions and education are among the key factors related to life expectancy. These factors influence our health and how long we live.
Life expectancy has been used as a measure of human development across regions and countries.
The researchers built a model that simulates the probability of getting infected by COVID-19 and the probability of dying from it. The model also had the probability of dying from another cause for a period of one year. The different fatality rates from the disease for different age groups have been looked into by the model.
They then calculated the impact of COVID-19 on life expectancy by reconstructing life tables and life expectancies from the simulation and comparing them with those used for the inputs. The study found that at very low prevalence rates, the COVID-19 pandemic would not affect life expectancy.
However, at prevalence rates of only two per cent, the disease could cause a drop in life expectancy in countries where average life expectancy is high – roughly around 80 years.
“At 10 per cent prevalence, the loss in life expectancy is likely to be above one year in high life-expectancy countries such as those in Europe and North America,” Morois said.
“At 50 per cent, it would translate into three to nine years of life lost in high life-expectancy regions. In less developed regions, the impact is smaller given that there is already lower survival at older ages,” he added.
However, Morois noted that even in the most affected regions, the life expectancy will likely recover once the pandemic is over. This type of analysis is useful to decision makers as it shows in broad strokes the potential cost of human lives lost due to the disease, according to the researchers.
The new study provides an important first estimate of the impact of COVID-19 on life expectancy, but new developments in healthcare or broader impacts of the pandemic on healthcare access or economic systems could also affect mortality rates and life expectancies.
